Roche un­corks new long-term da­ta as SMA ri­val­ry heats up

Lead­ing up to a reg­u­la­to­ry de­ci­sion in May that could give Roche a big leg up on Bio­gen and No­var­tis in the spinal mus­cu­lar at­ro­phy space, the Swiss phar­ma gi­ant is hop­ing some new da­ta will bol­ster its case.

Roche un­corked some long-term ef­fi­ca­cy and safe­ty da­ta for its block­buster SMA drug Evrys­di (ris­diplam) on Wednes­day, while al­so of­fer­ing an­oth­er peek at the in­ter­im re­sults for its RAIN­BOW­FISH study in new­borns un­der 2 months old.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER